Loren Morgan, MD
Interventional Cardiology · Columbia, SCNPI 1225340292
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,750 of the $60,189 with a category attached, or 64.4%. Boston Scientific accounts for 86.3% of it on its own, with 33 other manufacturers making up the rest. 2025 is the largest year on record at $27,138, more than ten times the $1,271 reported in 2019. Among interventional cardiology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $139.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$52K
- Abbott$3K
- Medtronic$1K
- Novartis$474
- AstraZeneca$469
- Johnson & Johnson$384
- plus $3K from 28 others
Across 25 payments — averaging $2679.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$67K
What the payments were for
- Speaking & faculty fees$38,75064%
- Grants$1350%
- Travel & lodging$10,37517%
- Food & beverage$10,85718%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 165 | $51,946 |
| Abbott | 44 | $3,006 |
| Medtronic(2 entities) | 15 | $1,366 |
| Novartis | 34 | $474 |
| AstraZeneca | 30 | $469 |
| Johnson & Johnson | 31 | $384 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $383 |
| Edwards Lifesciences | 7 | $344 |
| Cardiva Medical, Inc. | 12 | $251 |
| Amgen | 13 | $213 |
| Acist Medical Systems, Inc. | 7 | $196 |
| Abiomed | 3 | $164 |
| Pfizer | 11 | $155 |
| Shockwave Medical, Inc | 2 | $142 |
| E.r. Squibb & Sons, L.L.C. | 6 | $86 |
| Kestra Medical Technology Services, Inc. | 4 | $79 |
| Merck | 4 | $69 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 3 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $49 |
| Cardiovascular Systems Inc. | 7 | $44 |
| Biosense Webster, Inc. | 1 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Philips North America LLC | 1 | $26 |
| Boehringer Ingelheim | 2 | $26 |
| Biotronik Inc. | 1 | $22 |
| Terumo Medical Corporation | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| ZOLL Medical Corporation | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Bayer | 1 | $15 |
| Cardinal Health 200 LLC | 1 | $13 |
| Acutus Medical, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,189 in reported general payments places this provider in the 90th percentile of 117 interventional cardiology providers in South Carolina.
See all interventional cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $133,949 |
| Repatha SureclickEvolocumab | 85 | $101,810 |
| XareltoRivaroxaban | 45 | $46,249 |
| EntrestoSacubitril/Valsartan | 38 | $32,462 |
| JardianceEmpagliflozin | 26 | $29,542 |
| Praluent PenAlirocumab | 24 | $29,160 |
| FarxigaDapagliflozin Propanediol | 31 | $17,758 |
| BrilintaTicagrelor | 30 | $16,699 |
| Metoprolol Succinate | 178 | $2,804 |
| ClopidogrelClopidogrel Bisulfate | 244 | $2,788 |
| Rosuvastatin Calcium | 148 | $2,761 |
| Atorvastatin Calcium | 222 | $2,607 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 14 | $2,301 |
| Clonidine | 24 | $1,471 |
| Bumetanide | 23 | $1,465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $155 | $133,949182 claims |
| Johnson & JohnsonXarelto | $384 | $46,24945 claims |
| AstraZenecaFarxiga, Brilinta | $469 | $34,45761 claims |
| NovartisEntresto | $474 | $32,46238 claims |
| Boehringer IngelheimJardiance | $26 | $29,54226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 interventional cardiology providers in South Carolina.
Other interventional cardiology in Columbia
- Michael CryerColumbia$92K
- Vince VismaraColumbia$60K
- Patrick HallColumbia$50K
- George YankeyColumbia$41K
- Michael FosterColumbia$23K
- Matthew CantrellColumbia$21K
- Christopher HuffmanColumbia$21K
- Gopi ShahColumbia$16K
- Katrina BidwellColumbia$15K
- Guillermo PinedaColumbia$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.